Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 24, 2026, 12:09 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 88 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
AMD, nAMD, Wet Age-related Macular Degeneration, wAMD, WetAMD, CNV
Interventions
ABBV-RGX-314 Dose 1, ABBV-RGX-314 Dose 2, Aflibercept (EYLEA®)
Genetic · Biological
Lead sponsor
AbbVie
Industry
Eligibility
50 Years to 89 Years
Enrollment
735 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
107
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Bakersfield, California + 94 more
Conditions
Macular Degeneration
Interventions
ranibizumab, aflibercept injection (VEGF Trap-Eye, BAY86-5321)
Biological
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
50 Years and older
Enrollment
1,217 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
176
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 144 more
Conditions
Macular Degeneration
Interventions
Epi-Rad90™ Ophthalmic System, ranibizumab
Device · Drug
Lead sponsor
NeoVista
Industry
Eligibility
50 Years and older
Enrollment
494 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
23
States / cities
Phoenix, Arizona • Tucson, Arizona • Beverly Hills, California + 18 more
Conditions
Subfoveal Choroidal Neovascularization, Age-Related Maculopathy
Interventions
700 ug dexamethasone, ranibizumab, sham
Drug · Biological · Other
Lead sponsor
Allergan
Industry
Eligibility
50 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
2
States / cities
Fort Myers, Florida • Abilene, Texas
Conditions
Retinal Hemorrhage, Macular Degeneration
Interventions
vitrectomy with subretinal lucentis
Drug
Lead sponsor
Corewell Health East
Other
Eligibility
50 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Royal Oak, Michigan
Conditions
Neovascular Age Related Macular Degeneration
Interventions
OCT, Multifocal ERG, Microperimetry, Ranibizumab Ophthalmic
Device · Drug
Lead sponsor
Retina Macula Institute
Other
Eligibility
50 Years and older
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Torrance, California
Conditions
Macular Degeneration
Interventions
Abicipar Pegol, Ranibizumab, Sham Procedure
Drug · Other
Lead sponsor
Allergan
Industry
Eligibility
50 Years and older
Enrollment
949 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
73
States / cities
Birmingham, Alabama • Gilbert, Arizona • Phoenix, Arizona + 65 more
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Dosing Study of Ranibizumab for Diabetic Retinal and Macular Edema

NCT01476449
Conditions
Diabetic Retinopathy, Macular Edema
Interventions
Ranibizumab
Drug
Lead sponsor
Retina Vitreous Associates of Florida
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2016
U.S. locations
2
States / cities
Clearwater, Florida • St. Petersburg, Florida
Conditions
Retinopathy of Prematurity
Interventions
Ranibizumab, Laser therapy
Drug · Procedure
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
Not listed
Enrollment
224 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
12
States / cities
Loma Linda, California • Sacramento, California • Aurora, Colorado + 9 more
Conditions
Neovascular Age-related Macular Degeneration
Interventions
Ranibizumab (Lucentis)
Drug
Lead sponsor
University of Miami
Other
Eligibility
50 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Miami, Florida
Conditions
Age-Related Macular Degeneration (AMD)
Interventions
PAN-90806 Ophthalmic Solution, Lucentis
Drug
Lead sponsor
PanOptica, Inc.
Industry
Eligibility
50 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
22
States / cities
Colorado Springs, Colorado • Winter Haven, Florida • Shawnee Mission, Kansas + 19 more
Conditions
Macular Degeneration
Interventions
Ranibizumab
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
50 Years and older
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
50
States / cities
Mesa, Arizona • Phoenix, Arizona • Encino, California + 43 more
Conditions
Age-related Macular Degeneration (AMD)
Interventions
Aflibercept, Ranibizumab, Bevacizumab
Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 85 Years
Enrollment
331,541 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
East Hanover, New Jersey
Conditions
Neovascularization, Choroidal, Macular Degeneration, Age-Related
Interventions
Faricimab, Ranibizumab, Sham Procedure
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
50 Years and older
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
25
States / cities
Phoenix, Arizona • Tucson, Arizona • Bakersfield, California + 22 more
Conditions
Neovascular Age-Related Macular Degeneration
Interventions
Fovista™, Lucentis®, Avastin®, Eylea®
Drug
Lead sponsor
Retinal Consultants of Arizona
Other
Eligibility
50 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Phoenix, Arizona
Conditions
Recalcitrant Wet Age-related Macular Degeneration
Interventions
Ranibizumab
Drug
Lead sponsor
Northern California Retina Vitreous Associates
Other
Eligibility
50 Years and older
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2018
U.S. locations
1
States / cities
Mountain View, California
Conditions
Ocular Histoplasmosis Syndrome
Interventions
ranibizumab
Drug
Lead sponsor
Retina Associates of Kentucky
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2009
U.S. locations
1
States / cities
Lexington, Kentucky
Conditions
Diabetic Retinopathy
Interventions
Squalamine Lactate Ophthalmic Solution 0.2%
Drug
Lead sponsor
Starr Muscle
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
1
States / cities
New Brunswick, New Jersey
Conditions
Age-Related Macular Degeneration
Interventions
2.0 mg DE-122 Injectable Solution + Lucentis, 4.0 mg DE-122 Injectable Solution + Lucentis, Lucentis
Drug
Lead sponsor
Santen Inc.
Industry
Eligibility
50 Years and older
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
10
States / cities
Gilbert, Arizona • Beverly Hills, California • Mountain View, California + 7 more
Conditions
Age Related Macular Degeneration
Interventions
ranibizumab (Lucentis(R))
Drug
Lead sponsor
Lawrence S. Morse, MD
Other
Eligibility
50 Years and older
Enrollment
131 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2014
U.S. locations
1
States / cities
Sacramento, California
Conditions
Diabetic Macular Edema
Interventions
Ranibizumab
Drug
Lead sponsor
Vitreo-Retinal Associates, PC
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Worcester, Massachusetts
Conditions
Pain
Interventions
Eye injection by 30 or 32 gauge needle
Device
Lead sponsor
Retina Health Center
Industry
Eligibility
Not listed
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Fort Myers, Florida
Conditions
Radiation Retinopathy
Interventions
ranibizumab 2.0 mg
Drug
Lead sponsor
The New York Eye Cancer Center
Other
Eligibility
21 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
New York, New York
Conditions
Age-related Macular Degeneration
Interventions
Ranibizumab 0.5mg
Drug
Lead sponsor
Leonard Feiner, MD, PhD
Other
Eligibility
50 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
2
States / cities
Teaneck, New Jersey • Vauxhall, New Jersey